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Two regions within the HCV genome, hypervariable region 1 (HVR1) within the envelope (E)2 region and the PKR-binding
domain (PKRbD) comprising the interferon sensitivity determining region (ISDR) within the nonstructural (NS)5A protein, have
been reported to correlate with the outcome of antiviral treatment. Recently, a PKR/eIF2a phosphorylation homology domain
(PePHD) within the E2 protein of HCV-1 isolates was described to inhibit PKR in vitro. PePHD deleted HCV-1 mutants remain
capable of binding PKR to some extent while inhibition of PKR was found to be abolished by carboxy-terminal truncated E2
protein. The importance of mutations and quasispecies heterogeneity within the carboxy-terminal part of the E2 protein
comprising the PePHD of HCV-1b is unknown. Therefore, the carboxy-terminal part of the HCV E2 gene (codons 618–746)
including the PePHD was analyzed by sequencing of PCR products and individual clones of 41 HCV-1b-infected patients with
sustained (SR, n 5 12), end-of-treatment (ETR, n 5 10), or no virological (NR, n 5 19) response to antiviral therapy. Two highly
conserved regions (codons 658–673 comprising the PePHD and codons 675–704) and one variable region (codons 705–720)
were detected within the carboxy-terminal part of E2. No significant correlation of specific mutations or number of mutations
with treatment response was observed for the PePHD and the carboxy-terminal part of the E2 protein. Phylogenetic and
conformational analyses showed no specific clusters related to treatment outcome. Calculation of genetic complexity and
diversity based on nucleotide sequence analyses of 20 individual clones per patient showed no differences between matched
SR, ETR, and NR patients. However, calculation of genetic complexity and diversity on the basis of amino acid sequences
showed significantly lower normalized Shannon entropy as well as mean Hamming distances for SR patients than in ETR and
NR patients (P 5 0.029 and P 5 0.027, respectively). This indicates that patients achieving a sustained virological response
to interferon-a-based antiviral therapy may elicit more effective immunological pressure, resulting in continuous clearing of
individual variants of HCV quasispecies. © 2001 Academic Press
Key Words: hepatitis C virus; genetic complexity; genetic diversity; envelope (E)2 protein; double-stranded RNA-activated
protein kinase (PKR)-eIF2a phosphorylation homology domain (PePHD); nonstructural (NS)5A protein; double-stranded
RNA-activated protein kinase (PKR)-binding domain; secondary structure prediction.
cINTRODUCTION
Hepatitis C virus (HCV) is a positive-strand RNA virus
leading to chronic hepatitis with subsequent develop-
ment of cirrhosis and its sequelae (Alter et al., 1992; Saito
et al., 1990). Current standard treatment with interferon-a
(IFN-a) in combination with ribavirin achieves sustained
irological response, defined as undetectable HCV RNA
4 weeks after end of treatment, in approximately 40% of
1 Part of this article was presented at the 51st Annual Meeting of the
merican Association for the Study of Liver Diseases, Dallas, October
7–31, 2000.
2 Sequence data from this article have been deposited with the
EMBL/GenBank Data Libraries under Accession Nos. AJ343961–
AJ344001.
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150ases (Poynard et al., 1998; McHutchison et al., 1998).
Two regions within the HCV genome are known to be
potentially important for virological outcome after antivi-
ral therapy: hypervariable region 1 (HVR1) within the
amino-terminal part of the envelope 2 (E2) region, and
the RNA-activated protein kinase (PKR)-binding domain
(PKRbD) comprising the interferon sensitivity determin-
ing region (ISDR) within the carboxy-terminal part of the
nonstructural (NS)5A protein. Reported results concern-
ing the correlation of quasispecies heterogeneity within
HVR1 (Polyak et al., 1997; Le Guen et al., 1997; Sandres
et al., 2000; Lopez-Labrador et al., 1999; Nakazawa et al.,
1994; Moribe et al., 1995; Kanazawa et al., 1994; Koizumi
et al., 1995; Shindo et al., 1996; Okada et al., 1992) and
mutations within PKRbD/ISDR (Enomoto et al., 1996;
Chayama et al., 1997; Khorsi et al., 1997; Squadrito et al.,
1997; Zeuzem et al., 1997; Sa´iz et al., 1998; Sarrazin et al.,
1999, 2000a; Pawlotsky et al., 1998a) to treatment out-
come, however, are conflicting.
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151HETEROGENEITY OF CARBOXY-TERMINAL E2 REGION AND SENSITIVITY TO IFN-aRecently, another region within the HCV genome po-
tentially conferring sensitivity or resistance to antiviral
therapy was described. A PKR/eIF2a phosphorylation
omology domain (PePHD; codons 659–670) within the
arboxy-terminal part of the E2 protein, analogous to the
KRbD/ISDR (Gale et al., 1998; Brechot, 1999), was
hown to interact with double-stranded PKR function in
itro, suggesting a possible mechanism of HCV to evade
he antiviral effects of IFN-a. It was shown that E2 protein
from a HCV-1 isolate binds to and inhibits PKR in vitro,
whereas E2 proteins with a sequence derived from HCV
genotypes 2 and 3 abolished PKR interaction. PePHD-
deleted HCV-1 mutants remained capable of binding PKR
to some extent, indicating that also other regions within
the E2 protein may interact with PKR (Taylor et al., 1999).
The importance of quasispecies heterogeneity within
the carboxy-terminal part of the E2 protein in correlation
with treatment response is yet unexplored. Thus, in the
present study, sequence analyses of the carboxy-termi-
nal part of the E2 protein (codons 618–749) comprising
the PePHD (codons 659–670) were performed in 41 care-
fully characterized patients infected with genotype HCV-
1b. In matched patients with different treatment outcome
HCV E2 isolates were sequenced after cloning for reso-
lution of genetic complexity and diversity of HCV quasi-
species.
RESULTS
Forty-one patients chronically infected with HCV sub-
type 1b were assigned to three different groups accord-
ing to their response to antiviral therapy as described in
detail under Patients and Methods. Twelve patients
showed a sustained virological response (SR patients)
with undetectable HCV RNA 24 weeks after termination
of therapy. In 10 patients with undetectable HCV RNA at
FIG. 1. Location of the PePHD within the HCV E2 gene together w
rocessing of the E2 protein by a cellular signal peptidase is located at
t the E2/NS2 site (amino acid 809) and is incomplete at the E2/p7 si
nalyzed in the present study (codons 618–746) and the PePHD (codon
CV-1b prototype HCV-J (Kato et al., 1990).the end of treatment a relapse was observed (ETR pa-
tients). Nineteen patients revealed no virological re-
s
Nsponse to antiviral therapy at the end of treatment (NR
patients). From all patients, the carboxy-terminal part of
the HCV E2 region (codons 618–746 according to HCV-1b
prototype sequence HCV-J (Kato et al., 1990)) was ana-
lyzed (Fig. 1).
The PePHD within the carboxy-terminal part of the E2
protein of HCV-1 isolates (codons 659–670) but not of
HCV-2/3 isolates was described to bind and inhibit PKR
in vitro. PePHD-deleted mutants were able to inhibit PKR
to some extent, suggesting that other regions within the
E2 protein may also interact with PKR (Taylor et al., 1999).
In the present study, the carboxy-terminal part of the E2
protein (codons 618–746) including the PePHD (codons
659–670) was analyzed (Fig. 1).
Amino acid sequences of the E2 region from
pretreatment
Within the PePHD (codons 659–670) no sequence dif-
ferences exist between HCV-1b prototype sequences
HCV-J and HC-J4 (Kato et al., 1990; Okamoto et al.,
1992a). In comparison with HCV-1a prototype sequence
HCV-1 (Choo et al., 1991) only one amino acid exchange
s present (S668T). Comparison of HCV-1b prototype se-
uences with HCV-2a/b (HC-J6 and HC-J8) and HCV-3a
HCV-K3a) prototype sequences shows different amino
cid exchanges at positions 660, 661, 662, 663, and 667
Yamada et al., 1994; Okamoto et al., 1991, 1992b) (Fig. 2).
In the present study, analysis of 11/41 isolates from SR,
TR, and NR patients treated with IFN alone showed no
utations within the PePHD. Thus, no correlation be-
ween the PePHD sequence information and treatment
esponse was observed in the group of patients treated
ith IFN monotherapy. Altogether only one isolate of a
atient with SR showed an amino acid exchange (S660A)
ithin the PePHD in comparison with the consensus
open reading frame of the HCV polyprotein. The cleavage site for
2-terminus after amino acid 383. Carboxy-terminal cleavage is delayed
no acid 746). Furthermore, the carboxy-terminal part of the E2 protein
670) are indicated. Numbering of amino acid positions is according toith the
the NH
te (ami
s 659–equence. In the remaining 40 isolates of SR, ETR, and
R patients the consensus HCV-1b sequence was ob-
logical
E
s
3
1
152 SARRAZIN ET AL.served (Table 1). Thus, no correlation of mutations within
the PePHD and treatment outcome was observed inde-
pendent of IFN monotherapy or combination therapy with
ribavirin (Fig. 2).
FIG. 2. Sequence alignment of amino acid residues 618 to 746 ac
E2 protein) from pretreatment isolates of HCV-1b-infected patients.
indicate residues identical to the consensus sequence calculated fro
(Kato et al., 1990), HC-J4 (Okamoto et al., 1992a), HCV-1 (Choo et a
HCVK3a (Yamada et al., 1994) are shown as reference sequences fo
vertical lines indicate the PePHD (amino acids 659–670), whereas t
(E2var, amino acids 705–720). SR1–12, isolates of patients with susta
with relapse after treatment; NR1–19, isolates of patients without viro
combination therapy IFN-a plus ribavirin.
TABLE 1
Mutations in Different Parts of the Carboxy-Terminal E2 Gene
in HCV-1b-Infected Patients
Median number of
mutations ina
SR patients
(n 5 12)
ETR patients
(n 5 10)
NR patients
(n 5 19)
E2618–746
b 6.5 (1–12) 3 (2–5) 6 (1–12)
2659–670 (PePHD)
c 0 (0–1) 0 0
E2705–720 (E2var)
d 3 (0–6) 1 (0–3) 2 (0–7)
a Median number of mutations (range) in comparison with the con-
ensus sequence of HCV-1b isolates.
b Carboxy-terminal part of the E2 gene, including PePHD and 59-,
9-flanking regions; codons 618–746 according to HCV-J (Kato et al.,
990).
c PePHD; codons 659–670 according to HCV-J (Kato et al., 1990).
d Variable region within the carboxy-terminal part of the E2 gene;
codons 705–720 according to HCV-J (Kato et al., 1990).Within the carboxy-terminal part of the E2 protein
(codons 618–746) flanking the PePHD, multiple amino
acid differences exist between the reference sequences
for HCV-1a/b, HCV-2a/b, and HCV-3a prototypes (Fig. 2).
Sequence analyses of the 41 isolates in comparison with
the consensus sequence showed two highly conserved
regions within the carboxy-terminal part of the E2 protein
from codon 658 to 673 (comprising the PePHD) and
downstream from codon 675 to 704 (Fig. 3). Between this
conserved region (codons 675–704) and the hydrophobic
anchor domain of the E2 protein starting at codon 718 a
highly variable region was observed (E2var, codons 705–
720, Figs. 2 and 3).
Within the carboxy-terminal part of the E2 protein
(codons 618–746) the median number of mutations com-
pared with the consensus sequence was 6.5 (range
1–12) in SR patients, 3 (range 2–5) in ETR patients, and 6
(range 1–12) in NR patients (Table 1). Differences be-
tween virological responders (SR and ETR patients) and
g to the open reading frame of HCV-J (amino acids 235–363 of the
acid residues are indicated by standard single-letter code. Dashes
1 isolates investigated (cons). Additionally, the sequences of HCV-J
), HC-J6 (Okamoto et al., 1991), HC-J8 (Okamoto et al., 1992b), and
-1b, HCV-1a, HCV-2a, HCV-2b, and HCV-3a subtypes. The unbroken
ken vertical lines comprise the E2 carboxy-terminal variable region
rological response to antiviral therapy; ETR1–10, isolates of patients
response to antiviral therapy. The x’s indicate patients who receivedcordin
Amino
m all 4
l., 1991
r HCV
he bro
ined vinonresponders (NR patients) as well as between SR and
NR patients were not significant. Analyses of the variable
3t
(
w
e
p
t
a
9
w
i
S
i
g
t
w
c
t
t
n
v
A
m
(
c
i
w
m
t
p
i
6
a
t
r
a
d
7
p
t
c
(
c
b
a
r
I
s
T
s
t
153HETEROGENEITY OF CARBOXY-TERMINAL E2 REGION AND SENSITIVITY TO IFN-aregion from codon 705 to 720 showed a median of 3
(range 0–6) mutations in SR patients, 1 (range 0–3) mu-
tation in ETR patients, and 2 (range 0–7) mutations in NR
patients. As for the complete carboxy-terminal part in-
cluding the highly conserved regions of the E2 protein,
differences between virological responders (SR and ETR
patients) and nonresponders (NR patients) as well as
between SR and NR patients were not significant.
Mean pretreatment viremia was 7.2 3 106 (median
.6 3 106) in patients with 1–4 mutations and 11.9 3 106
(median 6.1 3 106) in patients with more than four mu-
ations within the carboxy-terminal part of the E2 region
codons 618–746). Differences between the two groups
ere statistically not significant. Furthermore, no differ-
nces in the number of mutations within the different
arts of the E2 protein were observed between the pa-
ients treated with IFN-a with or without ribavirin.
Phylogenetic and conformational analyses of E2
sequences
Evolutionary distance calculation based on the E2
amino acid sequences (codons 618–746) was performed
for phylogenetic analysis. No cluster in correlation with
treatment response was observed because isolates of
SR, ETR, and NR patients were scattered throughout the
phylogenetic tree (Fig. 4). To further elucidate potential
FIG. 3. Mutational frequencies within the carboxy-terminal part of the
E2 protein (codons 618–740) from pretreatment isolates of HCV-1b-
infected patients. Smoothed values are obtained using Gaussian ker-
nel weights with a bandwidth (standard deviation) of 6.5 amino acids.
SR patients are represented by the dark gray shaded area, ETR pa-
tients are represented by the gray shaded area, and NR patients are
represented by the lightest shaded area. The PePHD from codon 659 to
670 and the carboxy-terminal highly variable region (E2var) from codon
705 to 720 are indicated by vertical lines.differences between sensitive and resistant HCV strains,
a secondary structure conformational analysis was per-
o
lformed. The secondary structure of each strain (codons
618–746) was calculated using the double prediction
method of Dele´age and Roux (1987). In this method four
possibilities for each amino acid residue are given: helix
(H), b-sheet (E), turn (T), and coil (C). The majority of
mino acid mutations observed in isolates of SR (70/75,
3%), ETR (27/30, 90%), and NR patients (95/103, 92%)
ere conservative. Nonconservative mutations concern-
ng hydrophobic amino acids were rare in patients with
R, ETR, and NR, respectively, and no statistically signif-
cant differences were observed between the three
roups. The majority of hydrophobic amino acid muta-
ions within the variable region from codon 705 to 720
ere conservative. The conformational similarities were
alculated using an identity matrix and a tree was drawn
o show the relationship of the different strains based on
heir secondary structure. However, as in the phyloge-
etic analyses no cluster of isolates correlating with
irological treatment outcome was observed (Fig. 5).
nalyses of HCV quasispecies heterogeneity
Cloning and sequencing of 20 isolates obtained from
atched patients with SR (n 5 5), ETR (n 5 5), and NR
n 5 5) were performed for analyses of HCV quasispe-
ies heterogeneity (Figs. 6A–6C). Patients’ age, histolog-
cal grading and staging, and pretreatment viral load
ere similar in the three groups (Table 2). Additional
utations within HCV-PePHD quasispecies were de-
ected in only two SR patients and one NR patient. In
atient SR10 serine was replaced by alanine (codon 660)
n 2 of 20 clones (Fig. 6A). In patient SR7 proline at codon
64 was replaced by serine in 1 of 20 clones (Fig. 6A),
nd in patient NR12 serine at codon 660 was replaced by
hreonine and leucine at codon 666 by proline in 1 clone,
espectively (Fig. 6C). In the remaining clones of SR, ETR,
nd NR patients, no mutations within the PePHD were
etected.
Within the carboxy-terminal part of E2 (codons 618–
46) numerous mutations were found in SR, ETR, and NR
atients (Figs. 6A–6C). However, no significant correla-
ion of the number of mutations within the complete
arboxy-terminal part of E2 (codons 618–746), the PePHD
codons 659–670), and the highly variable region (E2var,
odons 705–720) with treatment response was observed
etween the three groups. Furthermore, no specific
mino acid exchanges were correlated with virological
esponse (Figs. 6A–6C). Analysis of patients treated with
FN alone (SR, ETR, and NR patient, respectively)
howed no mutations within the PePHD quasispecies.
hus, a correlation of mutations within the PePHD qua-
ispecies and virologic treatment response to IFN mono-
herapy was not observed. Comparison of sequences
btained after end of treatment with pretreatment iso-
ates in ETR and NR patients showed different mutational
antivira
numb
154 SARRAZIN ET AL.patterns in two of five ETR patients and in all NR patients
(Figs. 6B and 6C).
For further analyses of the quasispecies, heterogene-
ity genetic complexity as well as genetic diversity was
calculated based on nucleotide and corresponding
amino acid sequences (Figs. 6A–6C) of the five SR, ETR,
and NR patients, respectively (Table 2). Genetic complex-
ity calculated by Shannon entropy on the basis of nucle-
otide sequences showed no significant differences be-
tween SR (0.758), ETR (0.816), and NR (0.829) patients
(Fig. 7A). However, mean genetic complexity based on
amino acid sequences calculated by Shannon entropy
was lower in SR patients (0.306) than in ETR (0.382) and
NR patients (0.548). The mean genetic complexity in SR
FIG. 4. Phylogenetic tree of HCV-1b isolates (amino acids 618–746).
is shown as reference sequence. SR1–12, strains of patients with susta
relapse after therapy; NR1–19, strains of patients without response to
and HCV-1b. Distance scale: 10% sequence dissimilarity. Internal nodepatients was significantly lower than that in NR patients
(one-tailed P 5 0.038). In addition, the mean geneticcomplexity differs significantly between all three groups
(P 5 0.029; Fig. 7B). Thus, nucleotide mutations leading
to amino acid exchanges were detected more frequently
in NR patients than in ETR and SR patients.
For genetic diversity calculated by mean Hamming
distances on the basis of nucleotide sequences no sta-
tistically significant differences were observed in SR
(1.005), ETR (1.198), and NR (1.541) patients (Fig. 8A).
Analyses of genetic diversity based on amino acid se-
quences, however, showed lower mean Hamming dis-
tances in SR patients (0.550) than in ETR (0.644) and NR
(1.207) patients (Table 2). The mean genetic diversity in
SR patients was significantly lower than in NR patients
(one-tailed P 5 0.037). In addition, the mean genetic
nsensus sequence calculated from all 41 isolates investigated (cons)
ological response to antiviral therapy; ETR1–10, strains of patients with
l treatment; HCV-1, HCV-J, and HC-J4, prototype sequences of HCV-1a
ers represent bootstrap values (shown only for .50%).The co
ined virdiversity differs significantly between all three groups
(P 5 0.027; Fig. 8B).
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155HETEROGENEITY OF CARBOXY-TERMINAL E2 REGION AND SENSITIVITY TO IFN-aDISCUSSION
Virological response to antiviral therapy in HCV-in-
ected patients is influenced by host- and/or virus-related
actors. Because of highly different sustained response
ates to antiviral therapy between HCV genotypes (30%
n HCV-1 in comparison with 65% in HCV non-1 geno-
ypes), virus-related factors are apparently important.
wo HCV proteins have been shown to interact with
FN-a signal transduction pathways, thereby potentially
elping the virus to evade antiviral mechanisms. The
S5A protein has been shown in vitro to inhibit IFN-a-
induced PKR function through a PKR-binding domain.
FIG. 5. Tree of conformational similarities of HCV-1b isolates on the
from amino acids 618 to 746 of the E2 protein. The conformational ana
(cons) are shown as reference. SR1–12, strains of patients with sustain
relapse after therapy; NR1–19, strains of patients without response to
and HCV-1b. Distance scale: 10% sequence dissimilarity.However, the significance of these findings for individual
treatment outcomes is controversial in different clinical
e
4(Pawlotsky and Germanidis, 1999; Korth and Katze, 2000)
and functional investigations (Polyak et al., 1999; Pater-
son et al., 1999; Francois et al., 2000). More recently, the
CV E2 protein of HCV-1a/b isolates was also shown to
ind PKR and to inhibit PKR function in vitro through a
ePHD.
In the present study, the mutational pattern within the
arboxy-terminal part of the E2 protein comprising the
ePHD was investigated in 41 HCV-1b-infected patients
ith different treatment outcomes. Patients were well char-
cterized and categorized into three groups according to
heir different responses to antiviral therapy. Early respond-
of predicted secondary structure of corresponding sequences (Fig. 2)
f the consensus sequence calculated from all 41 isolates investigated
logical response to antiviral therapy; ETR1–10, strains of patients with
l treatment; HCV-1, HCV-J, and HC-J4, prototype sequences of HCV-1abasis
lyses o
ed virors with HCV RNA below 1000 copies/ml at treatment week
and undetectable HCV RNA at end of treatment with
156 SARRAZIN ET AL.
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157HETEROGENEITY OF CARBOXY-TERMINAL E2 REGION AND SENSITIVITY TO IFN-asubsequent sustained virological response (SR patients) or
relapse (ETR patients) were distinguished from nonre-
sponders with less than a 2log decline of HCV RNA at
treatment week 4 and detectable HCV RNA at end of treat-
ment and during follow-up (NR patients). In accordance
with recent studies (Sarrazin et al., 2000b; Polyak et al.,
2000; Abid et al., 2000) the PePHD within HCV-E2 was
found to be highly conserved in SR, ETR, and NR patients.
In only one patient with sustained virological response was
a mutation (S660A) observed within the PePHD and no
significant correlation was found between the number of
mutations and treatment outcome.
Within the carboxy-terminal part of the E2 protein se-
FIG. 6. Pretreatment quasispecies analyses of five SR (A), ETR (B), a
carboxy-terminal E2 protein (amino acids 618–746) were sequenced (t
alignments obtained from pretreatment serum samples by direct seq
sequencing of the carboxy-terminal E2 gene from posttreatment seru
standard single-letter code. Dashes indicate residues identical to the
sequence of HCV-J (Kato et al., 1990) is shown as the reference seque
whereas the broken vertical lines comprise the E2 carboxy-terminal
virological response to antiviral therapy; ETR2, 3, 5, 8, and 9, isolates of
without virological response at the end of treatment. The x’s indicate
numbers indicate individual clones from pretreatment sera. A vertical bquenced in the present study (codons 618–746) two
highly conserved regions (codons 658–673 including thePePHD and codons 675–704) and one highly variable
region with multiple mutations (codons 705–720) were
detected. Comparison of SR patients with NR patients
showed that neither individual amino acid mutations nor
the number of mutations within the carboxy-terminal part
of the E2 gene was correlated with treatment response.
Phylogenetic and conformational analyses also failed to
show clusters of patients with similar treatment out-
comes. In different studies an inverse correlation be-
tween the number of mutations within the ISDR/PKRbD
of the NS5A protein and pretreatment viremia was de-
scribed (Enomoto et al., 1996; Chayama et al., 1997;
Sarrazin et al., 2000a). In the present study, however, no
(C) patients. From each patient 20 clones of HCV quasispecies of the
bers 1–20 indicate the individual clones). In addition, the amino acid
g (0 pre) are shown. Furthermore, from ETR and NR patients direct
ples was performed (0 post). Amino acid residues are indicated by
sus sequence calculated from all 41 isolates investigated (cons). The
the HCV-1b subtype. The unbroken vertical lines indicate the PePHD,
le region. SR2, 7, 10, 11, and 12, isolates of patients with sustained
ts with relapse after therapy; NR4, 6, 11, 12, and 15, isolates of patients
ts who received combination therapy IFN-a plus ribavirin, whereas
cates a stop codon and an asterisk indicates a deletion of one codon.nd NR
he num
uencin
m sam
consen
nce of
variab
patiensuch correlation was observed for the carboxy-terminal
part of the E2 protein including the PePHD.
0
g
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q
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158 SARRAZIN ET AL.The HVR1 located at the amino-terminus of the E2
gene is considered to be a major target of neutralizing
antibodies and the variability in HVR1 is likely to result
from selective pressure by the immune system (van
Doorn et al., 1995). Acute resolving HCV infection has
recently been shown to be associated with relative evo-
lutionary stasis, whereas progression to chronic hepati-
tis was correlated with genetic evolution of HVR1 quasi-
species (Farci et al., 2000). In patients with chronic HCV
infection the correlation between HVR1 quasispecies
variability and treatment outcome was extensively inves-
tigated. Many studies showed that a higher degree of
variability in the HVR1 quasispecies correlates with
lower response rates to IFN-a treatment (Nagasaka et
al., 1996; Gonzalez-Peralta et al., 1996; Moribe et al.,
1995; Kanazawa et al., 1994; Koizumi et al., 1995; Shindo
et al., 1996; Hino et al., 2000; Pawlotsky et al., 1998b;
Okada et al., 1992); however, no such correlation was
observed in other studies (Le Guen et al., 1997; Sandres
et al., 2000; Lopez-Labrador et al., 1999; Nakazawa et al.,
1994). The discrepancies in these results may be related
to (1) HCV genotype distribution in different studies, (2)
methodology to assess quasispecies heterogeneity (i.e.,
bandshift assays or sequencing), (3) different assess-
ment and quantification of quasispecies heterogeneity,
and/or (4) different definitions of treatment outcome.
The importance of HCV quasispecies heterogeneity
outside the HVR1 in patients with chronic HCV infection
is unknown. In the present study, HCV quasispecies of
the carboxy-terminal part of the E2 protein (codons 618–
746 comprising the PePHD) were analyzed and corre-
lated with treatment response in carefully characterized
patients treated with IFN-a with or without ribavirin. Het-
erogeneity of HCV quasispecies was assessed by se-
quence analysis of 20 individual clones per patient and
genetic complexity as well as genetic diversity of HCV
quasispecies was calculated on the basis of both nucle-
otide and amino acid sequences. Quasispecies analyses
T
Clinical Characteristics and Quasispecies Analyses of Carbo
Agea
(years) HAIb
qRNAc
(copies/ml)
SR (n 5 5)e 48 6 11.7 2.6 6 0.8 15.7 3 106
ETR (n 5 5)e 59 6 6.7 2.6 6 0.8 12.9 3 106
NR (n 5 5)e 40 6 13.8 2.4 6 1 11 3 106
a Mean age (years) 6 SD. Differences between SR, ETR, and NR pa
b Mean histological activity index (HAI) of the liver 6 SD. Difference
c Mean quantitative HCV RNA levels from pretreatment serum samp
d Mean genetic complexity and genetic diversity of HCV quasispecie
Shannon entropy and Hamming distances, respectively.
e Quasispecies analyses was performed by sequencing of 20 indivion the basis of amino acid sequences showed signifi-
cantly lower genetic complexity as well as genetic diver-sity in SR patients than in NR patients (P 5 0.038 and P 5
.037, respectively). In addition, a trend toward lower
enetic complexity and diversity was observed between
R and ETR patients on the basis of amino acid se-
uences (P 5 0.087 and P 5 0.057, respectively).
The differences between SR, ETR, and NR patients
were not significant when analyses of quasispecies
complexity and diversity were based on nucleotide se-
quences. Thus, in NR patients a larger number of nucle-
otide mutations were associated with amino acid ex-
changes compared with ETR and SR patients. These
findings may be explained by an increased evolution of
more diverse HCV quasispecies in NR patients or by a
more effective immunological response in SR and ETR
patients, resulting in continuous clearance of individual
variants of HCV quasispecies. In accordance with the
study of Farci et al. (2000) showing more pronounced
genetic evolution of HCV quasispecies within HVR1 dur-
ing development of chronic than in acute resolving HCV
infection, we have detected a lower genetic complexity
and diversity in patients with chronic HCV infection and
sustained virological response resulting from more ef-
fective control of quasispecies evolution compared with
ETR and NR patients. According to this hypothesis, qua-
sispecies heterogeneity must not differ at the nucleotide
level in SR, ETR, and NR patients, because conservative
nucleotide mutations are not recognized by the immune
system.
In two recent studies of mainly HCV non-1-infected
patients, no correlation between the nucleotide and
amino acid sequence entropy of the HVR1 and PePHD
(and flanking regions) quasispecies and response to
antiviral treatment was observed (Sandres et al., 2000;
Sarrazin et al., 2000b). In the present study, as well as in
the study by Farci et al. (2000), only HCV-1b-infected
patients were investigated. Thus, evolution of HCV qua-
sispecies and the significance of quasispecies hetero-
geneity for treatment outcome may differ between pa-
inal E2 Gene (codons 618–746) of HCV-1b-Infected Patients
Genetic complexityd Genetic diversityd
eotide Amino acid Nucleotide Amino acid
0.179 0.306 6 0.190 1.005 6 0.796 0.550 6 0.503
0.119 0.382 6 0.058 1.198 6 0.676 0.644 6 0.089
0.117 0.548 6 0.077 1.541 6 0.361 1.207 6 0.202
were not significant.
een SR, ETR, and NR patients were not significant.
fferences between SR, ETR, and NR patients were not significant.
calculated on the basis of amino acid and nucleotide sequences by
nes in five SR, ETR, and NR patients, respectively.ABLE 2
xy-Term
Nucl
0.758 6
0.816 6
0.829 6
tients
s betw
les. Di
s 6 SDtients infected with HCV-1 or HCV non-1 isolates.
Taken together, we observed two conserved regions
159HETEROGENEITY OF CARBOXY-TERMINAL E2 REGION AND SENSITIVITY TO IFN-a(one comprising the PePHD) and one variable region
within the carboxy-terminal part of the E2 protein of
HCV-1b isolates. Neither the number of mutations nor
specific mutations in the carboxy-terminal E2 protein
were correlated with treatment outcome. However, anal-
yses of quasispecies heterogeneity based on amino acid
FIG. 7. Genetic complexity of HCV quasispecies calculated by nor-
malized nucleotide (A) and amino acid (B) sequence entropy (Shannon
entropy) in five SR, ETR, and NR patients (according to sequences
shown in Fig. 6). The horizontal bars indicate the median genetic
distances of the cohort. P values from Mann–Whitney U and Kruskal–
Wallis tests are given for comparison of different groups.sequences showed significantly lower genetic complex-
ity as well as genetic diversity in patients with sustainedvirological response compared with virological nonre-
sponders. This indicates that patients achieving a sus-
tained virological response to interferon-a-based antivi-
ral therapy may elicit more effective immunological pres-
sure resulting in continuous clearing of individual
variants of HCV quasispecies.
PATIENTS AND METHODS
Patients
In the present study, we investigated 41 patients [26
men, 15 women, mean age 48 (range 23–72) years]
chronically infected with HCV subtype 1b, who received
antiviral therapy between 1997 and 1999 at the Hepatol-
ogy Outpatient Clinic of the University of Frankfurt (Ter-
tiary Referral Center). The diagnosis of chronic hepatitis
C was based on elevated serum aminotransferase levels
for at least 6 months, histological examination, and the
consistent detection of serum HCV RNA. Anti-HCV anti-
bodies (third-generation enzyme-linked immunosorbent
assay) were present in each patient. All patients were
negative for hepatitis B surface antigen and antibodies to
human immunodeficiency virus 1 and 2. Patients were
treated with 3 million units (MU) recombinant IFN-a three
times per week subcutaneously for 48 weeks. Thirty
patients received combination treatment with ribavirin
(1000 mg/day in patients #75 kg body weight or 1200
mg/day in patients .75 kg body weight).
Definition of treatment outcome
Virological nonresponse was defined by detectable
HCV RNA at the end of treatment. Furthermore, the initial
viral decline (pretreatment HCV RNA 2 HCV RNA at
week 4) had to be less than 2log to exclude patients with
breakthrough phenomena. End-of-treatment response
was defined by negative HCV RNA at the end of treat-
ment but relapse thereafter. Sustained virological re-
sponse was defined by the loss of detectable HCV RNA
at the end of treatment and 24 weeks after completion of
therapy. Serum HCV RNA was below 1000 copies/ml at
week 4 of treatment in all patients with SR and ETR.
Measurement of HCV RNA and HCV genotyping
Serum was prepared in a laminar flow bench and
frozen at 280°C. After extraction of HCV RNA from se-
rum, complementary DNA was generated using random
hexamers. Detection of serum HCV RNA at week 4, at the
end of treatment, and at the end of the follow-up period
was performed by reverse transcription-polymerase
chain reaction (RT-PCR) according to the manufacturer’s
instructions (Amplicor HCV 2.0 Monitor; Roche Diagnos-
tic Systems Inc., Mannheim, Germany). The lower detec-
tion limit of the assay was 1000 copies/ml. Quantification
of HCV RNA in pretreatment sera of patients was per-
formed by the branched DNA method using the Quanti-
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160 SARRAZIN ET AL.plex HCV RNA assay (Version 2.0, Bayer Diagnostics,
Emeryville, CA). Genotyping of HCV (according to the
classification of Simmonds (1995)) was performed by
reverse hybridization assay (INNO LiPA HCV-II; Innoge-
netics, Ghent, Belgium). All contamination prevention
measures suggested by Kwok and Higuchi (1989) were
strictly applied.
Amplification of HCV E2 cDNA by PCR
FIG. 8. Genetic diversity of HCV quasispecies calculated by Ham-
ing distances on the basis of nucleotide (A) and amino acid (B)
equences in five SR, ETR, and NR patients (according to sequences
hown in Fig. 6). The horizontal bars indicate the median genetic
istances of the cohort. P values from Mann–Whitney U and Kruskal–
allis tests are given for comparison of different groups.The following set of primers was constructed for nested
PCR amplification of E2 cDNA of patients infected with
1
qHCV-1b isolates (numbering according to the HCV-1b pro-
totype HCV-J (Kato et al., 1990)); external sense 1bE21s
(59-GGGCCCTGGTTGAAACC-39; nucleotide position 2127–
2143), external antisense 1bE26a (59-GCCGCATTGAGGAC-
AC-39; nucleotide position 2583–2599) and internal sense
bE24s (59-GACTACCCATACAGGCTCTGG-39; nucleotide
osition 2157–2177), internal antisense 1bE27a (59-GAG-
ACCACCAGGTTCTC-39; nucleotide position 2574–2591)
r 1bE28a (59-ACCAGGTTCTCTAAGG-39; nucleotide posi-
ion 2569–2584). For the first and second rounds of nested
CR 35 cycles of 95°C for 30 s, 55°C for 50 s, and 72°C for
min were performed after an initial denaturation step at
5°C for 12 min in a PE9700 thermocycler (Perkin–Elmer
etus, Norwalk, CT). The resulting amplification product
as analyzed on a 1.8% agarose gel stained with ethidium
romide. From 7 of 41 patients partial sequence information
f the E2 gene (codons 632–698) was previously reported
Sarrazin et al., 2000b).
equence analysis
For direct sequencing of the E2 region, 40 ml of the
second-round PCR product was purified with Microcon
100 (Amicon, Witten, Germany). Sequence analysis was
performed according to the manufacturer’s instructions
(Big Dye Deoxy Terminators; Applied Biosystems, Weit-
erstadt, Germany). Sequencing of the positive strand and
the minus strand was performed by an automated DNA
sequencer (Applied Biosystems 310 DNA Sequencer).
The deduced amino acid sequences of the E2 region
(codons 618–746 according to HCV-1b prototype HCV-J
(Kato et al., 1990)) were compared with the E2 sequences
identified in the prototype isolates for HCV-1a (HCV-1
(Choo et al., 1991)), HCV-1b (HCV-J and HC-J4 (Kato et al.,
1990; Okamoto et al., 1992a)), and the consensus se-
uence of all HCV-1b isolates (cons) investigated in the
resent study. For quasispecies analyses, purified PCR
roducts were ligated with the pCR 2.1 vector (Invitrogen,
V, Leek, The Netherlands) and subsequently trans-
ormed into Escherichia coli competent cells according
o the manufacturer’s instructions. Twenty individual
lones from each sample were sequenced using internal
ense and antisense primers as described. In five pa-
ients from each group (SR, ETR, and NR) a HCV E2
uasispecies analysis was performed. Patients were se-
ected by a computer program matching for age, histo-
ogical stage, and pretreatment viral load. Furthermore,
he condition was made that one patient in each group
as treated with IFN alone.
hylogenetic and conformational analyses
Multiple alignment of amino acid sequences and cal-
ulation of the consensus sequence (cons) were per-
ormed using CLUSTALX1.64b software (Thompson et al.,
994). Construction of the phylogenetic tree of E2 se-
uences obtained from HCV isolates of the investigated
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161HETEROGENEITY OF CARBOXY-TERMINAL E2 REGION AND SENSITIVITY TO IFN-apatients was performed using the program Treecon for
Windows (Version 1.3b) (Van de Peer and De Wachter,
1994). An identity protein weight matrix was used to
estimate the evolutionary distance. Kimura correction
was used to correct for multiple substitutions (Kimura,
1983). The phylogenetic tree was constructed with the
neighbor-joining method of Saitou and Nei (1987). Boot-
strap resampling (1000 replicates) was utilized as a
pseudo-empirical test on the reliability of the tree topol-
ogy (Felsenstein, 1985). The secondary structure of re-
sulting proteins of the E2 sequences was predicted with
the double prediction method of Dele´age and Roux
(1987) implemented in ANTHEPROT V4.2 software
(Geourjon and Dele´age, 1995). This method is a combi-
nation of protein class predictions according to Na-
kashima et al. (1986) and Chou and Fasman (1978).
Multiple alignment of predicted secondary structures
was performed and an identity comparison matrix was
calculated, both using CLUSTALX1.64b (Thompson et al.,
1994).
Calculation of genetic complexity
The genetic complexity is defined as the number of
viral variants within HCV quasispecies (Gomez et al.,
1999). For determination of genetic complexity within the
E2 region (codons 618–746 according to HCV-1b proto-
type HCV-J (Kato et al., 1990)) the entropy was calculated,
which is defined in terms of the probabilities of the
different sequences or clusters of sequences that can
appear at a given time point. The measure is calculated
as S 5 2S i(pi In pi), where pi is the relative frequency of
ach sequence in the viral quasispecies. The normalized
ntropy, Sn was calculated as Sn 5 S/In N, is the total
umber of sequences analyzed (Wolinsky et al., 1996). Sn
theoretically varies from 0 (all isolates identical) to 1 (all
isolates are different). The normalized Shannon entropy
was calculated at both the nucleotide and the amino acid
levels on the basis of 20 HCV clones isolated from
pretreatment sera in matched patients with a sustained
(n 5 5), end-of-treatment (n 5 5), or no (n 5 5) virological
esponse to therapy.
alculation of genetic diversity
The genetic diversity is defined as the frequency of
utations within the different isolates of HCV quasispe-
ies. Determination of the genetic diversity in the differ-
nt sets of sequences of HCV quasispecies was per-
ormed by calculation of Hamming distances, which are
efined as the number of nucleotide or amino acid dif-
erences between two sequences, or (1-s) 3 100, where
s is the fraction of shared sites in two aligned nucleotide
sequences. The Hamming distance theoretically varies
from 0 (no genetic diversity) to 100 (maximum genetic
diversity). The mean Hamming distance is the average of
the values taken for all sequence pairs derived from asingle patient’s sample. The mean Hamming distances
were calculated at both the nucleotide and the amino
acid levels on the basis of 20 HCV clones isolated from
pretreatment sera of matched patients with a sustained
(n 5 5), end-of-treatment (n 5 5), or no (n 5 5) virological
esponse to therapy.
ata presentation
Clinical and biochemical characteristics of patients
re expressed as mean or median and range as appro-
riate. Distributions of continuous variables were ana-
yzed by the Mann–Whitney U test (one-tailed when test-
ng the primary hypothesis that virologic response is
ssociated with lower quasispecies complexity as well
s lower diversity) and the Kruskal–Wallis test (two
ailed). P values of ,0.05 were considered significant.
or presentation of the mutational frequencies in SR,
TR, and NR patients (codons 618–746) smoothed values
ere obtained using Gaussian kernel weights with a
andwidth (standard deviation) of 6.5 amino acids (Simo-
off, 1996).
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